Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Inclusion Criteria: * CML Ph+ (assessed by cytogenetic or FISH) * Acute phase with ≥ 20% bone marrow blasts (M0 to M6 , excluding M3) * Age ≥ 18 year at inclusion * PS grade 0 to 2 (ECOG) * Adequate and organ function, defined as the following: total bilirubin \<1.5x uln, sgpt \<3x uln, creatinine \<1.5x uln. * Informed consent signed up Exclusion Criteria: * active malignancy other than CML or non-melanoma cancer of the skin * current treatment with another investigational agent * patients with grade 3/4 cardiac disease or any other serious concurrent medical condition. * patients who are pregnant or nursing. All patients of childbearing potential must practice effective methods of contraception while on study. * patients with mental illness or other condition precluding their ability to give informed consent or to comply with study requirements patients with performans status 3-4